We are live on !
Find out more
Rangeley Capital Portfolio holdings
AUM
$109M
Turnover
49.06%
1-Year Est. Return
97.13%
This Fund
S&P 500
This Quarter Est. Return
+34.11%
1 Year Est. Return
+97.13%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
+$6.53M
(+6.3%)
Cap. Flow
-$6.26M
Cap. Flow % of AUM
Cap. Flow %
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
32.08%
Holding
212
New
75
Increased
28
Reduced
43
Closed
29
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nomad Foods
NOMD
|
+$1.34M |
| 2 |
Mountain Lake Acquisition Corp II
MLAA
|
+$1.27M |
| 3 |
Distribution Solutions Group
DSGR
|
+$1.26M |
| 4 |
enGene Therapeutics
ENGN
|
+$1.24M |
| 5 |
Abivax
ABVX
|
+$1.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$8.47M |
| 2 |
Leggett & Platt
LEG
|
+$2.1M |
| 3 |
Icon
ICLR
|
+$1.96M |
| 4 |
Kezar Life Sciences
KZR
|
+$1.8M |
| 5 |
Mister Car Wash
MCW
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.11% |
| 2 | Consumer Discretionary | 14.33% |
| 3 | Financials | 12.51% |
| 4 | Miscellaneous | 10.11% |
| 5 | Real Estate | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Keros Therapeutics
KROS
$225M
| $582K | 0.53% |
54,400
| – | – |
2025 Q1
5 quarters
|
|
52
D-Market Electronic Services & Trading
HEPS
$1.19B
| $582K | 0.53% |
200,000
| – | – |
2024 Q4
6 quarters
|
|
53
CALL
Meta Platforms (Facebook)
META
$1.61T
| $563K | 0.51% |
+1,000
| New | +$611K |
2026 Q2
0 quarters
|
|
54
Core Scientific Inc Tranche 1 Warrants
CORZW
$669M
| $553K | 0.51% |
21,600
-5,600
| -21% | -$94.3K |
2025 Q2
4 quarters
|
|
|
55
enGene Therapeutics
ENGN
$106M
| $528K | 0.48% |
+305,102
| New | +$1.24M |
2026 Q2
0 quarters
|
|
56
CALL
iShares Bitcoin Trust
IBIT
$65B
| $526K | 0.48% |
+15,800
| New | +$643K |
2026 Q2
0 quarters
|
|
57
E.W. Scripps
SSP
$192M
| $518K | 0.47% |
187,000
+101,510
| +119% | +$384K |
2026 Q1
1 quarter
|
|
58
General Purpose Acquisition Corp Units
GPACU
| $505K | 0.46% |
50,000
| – | – |
2025 Q4
2 quarters
|
|
59
Nektar Therapeutics
NKTR
$1.28B
| $489K | 0.45% |
+7,000
| New | +$512K |
2026 Q2
0 quarters
|
|
60
Klaviyo
KVYO
$5.9B
| $468K | 0.43% |
+31,000
| New | +$514K |
2026 Q2
0 quarters
|
|
61
Silicon Valley Acquisition Corp
SVAQ
$298M
| $466K | 0.43% |
+46,162
| New | +$461K |
2026 Q2
0 quarters
|
|
62
uniQure
QURE
$1.5B
| $461K | 0.42% |
10,000
-3,000
| -23% | -$78.5K |
2025 Q4
2 quarters
|
|
63
FutureCrest Acquisition Corp
FCRS
$367M
| $454K | 0.41% |
44,070
+3,367
| +8% | +$34.3K |
2026 Q1
1 quarter
|
|
|
64
iShares Bitcoin Trust
IBIT
$65B
| $453K | 0.41% |
+13,600
| New | +$553K |
2026 Q2
0 quarters
|
|
65
Alnylam Pharmaceuticals
ALNY
$30.5B
| $452K | 0.41% |
+1,500
| New | +$452K |
2026 Q2
0 quarters
|
|
66
Inhibikase Therapeutics
IKT
$212M
| $447K | 0.41% |
220,000
| – | – |
2026 Q1
1 quarter
|
|
67
Adicet Bio
ACET
$36.9M
| $440K | 0.4% |
50,892
-5,108
| -9% | -$40.3K |
2025 Q3
3 quarters
|
|
68
OnKure Therapeutics
OKUR
$100M
| $433K | 0.4% |
95,000
| – | – |
2025 Q2
4 quarters
|
|
69
Oaktree Acquisition Corp III Life Sciences
OACC
$263M
| $431K | 0.39% |
40,239
-20,949
| -34% | -$223K |
2025 Q3
3 quarters
|
|
70
Globa Terra Acquisition Corp Units
GTERU
$158M
| $422K | 0.39% |
40,361
| – | – |
2025 Q3
3 quarters
|
|
71
Fulcrum Therapeutics
FULC
$278M
| $420K | 0.38% |
+114,890
| New | +$699K |
2026 Q2
0 quarters
|
|
72
New America Acquisition I Corp Units
NWAX.U
| $414K | 0.38% |
40,000
| – | – |
2025 Q4
2 quarters
|
|
73
Corbus Pharmaceuticals
CRBP
$77.2M
| $413K | 0.38% |
44,000
-840
| -2% | -$7.95K |
2026 Q1
1 quarter
|
|
74
Arq
ARQ
$76M
| $400K | 0.37% |
+157,000
| New | +$390K |
2026 Q2
0 quarters
|
|
75
LSB Industries
LXU
$731M
| $378K | 0.35% |
+35,000
| New | +$468K |
2026 Q2
0 quarters
|
|
Similar funds
S2L
Rangeley Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Rangeley Capital held 212 positions worth $109M, up 6.3% from $103M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Rangeley Capital withdrew a net $6.26M in Q2 2026, closing 29 positions and reducing 43 holdings. Its most notable exit was Leggett & Platt, an estimated $2.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 29% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Rangeley Capital opened a new position in Nomad Foods worth $1.48M.
- Rangeley Capital's largest Q2 2026 buy was Nomad Foods: 135,000 shares worth $1.48M.
- Rangeley Capital added most to Distribution Solutions Group in Q2 2026, an estimated $1.26M increase.
- Rangeley Capital's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $8.47M.
- Rangeley Capital fully exited Leggett & Platt in Q2 2026, selling an estimated $2.1M.
- Rangeley Capital's ten largest holdings make up 32% of its $109M portfolio in Q2 2026.
- Rangeley Capital opened 75 new positions and closed 29 in Q2 2026.
- Rangeley Capital's portfolio value rose 6.3% quarter-over-quarter to $109M.
Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.